tbuckley/cabot-search huggingface dataset:
2408TiP DISCUS: A randomised phase II study of 3 vs 6 cycles of chemotherapy followed by maintenance avelumab in advanced urothelial cancer - Wearable devices and circulating biomarkers assessing quality of life and surrogate efficacy endpoints
Authors: F. Jackson-Spence, A. Pinto Marin, J. Puente, J. Molina-Cerrillo, S.A. Hussain, C. Ackerman, N. Bonsu, J. Kelly, Y. Loriot, T.B. Powles, E. Grande Pulido
Journal: Annals of Oncology (2023)
1742P Gender differences in incidence trends of early-onset GI cancer: The European perspective
Authors: I. Ben-Aharon, H.W.M. van Laarhoven, M.G. Guren, I. Baraibar Argota, N. Gordon, T.G. Goshen - Lago, R.H.A. Verhoeven, T. Sokop, R. Obermannova, F. Lordick
Journal: Annals of Oncology (2023)
1755P Carbohydrate quality index and incidence of obesity-related cancers: The Seguimiento Universidad de Navarra (SUN) project
Authors: M. Olmedo López-frías, M. Barbería-Latasa, M.J. Cobo, I. Zazpe, J.M. Aramendia, M. Bes-Rastrollo, M.Á. Martínez-González, E. Toledo
Journal: Annals of Oncology (2023)
1812P Exploration of germline (g) vs somatic (s) origin of homologous recombination repair (HRR) gene alterations and potential associations with antitumor activity in the HRR-deficient population from TALAPRO-2
Authors: S.M. Yip, K. Fizazi, N. Matsubara, A.A. Azad, J.Y. Joung, P.C. Fong, J. Carles Galceran, U.F.F. De Giorgi, R.J. Jones, G. Liu, A.P. Fay, E. Voog, S. Zschäbitz, J. Oldenburg, N. Di Santo, C.G. Healy, X. Lin, D. Laird, N. Agarwal
Journal: Annals of Oncology (2023)
1797P Application of novel machine learning model in [68Ga] Ga-PSMA-11 PET/CT: Predicting survival in oligometastatic prostate cancer patients
Authors: M. Dell'Oro, M.A. Ebert, J. Ong, M. McCarthy, C. Tang, R.J. Francis
Journal: Annals of Oncology (2023)

Biochemical recurrence is estimated to occur in ≥ 25% of patients with prostate cancer (PC) following primary curative therapy. Machine learning models are being developed for lesion detection and tracking to provide a comprehensive view of disease burden, allowing clinicians to quantify and predict effectiveness of treatment for individual lesions. This study applied novel AI-assisted technology to automatically extract features from [68Ga] Ga-PSMA-11 (PSMA) PET/CT images that correlate with treatment intervention and survival data to create a scoring system. Between 2015 and 2016, 185 men with oligometastatic PC had a baseline and follow-up PSMA PET/CT scan (at ∼6-months) whilst treated per standard clinical care. Lesions were quantified and matched between timepoints using AIQ Solutions technology. Imaging features were extracted from each patient, including change in basic features (SUVmax, SUVmean, and number of lesions at baseline), and heterogeneity features (intrapatient heterogeneity of disease and response). Univariate predictive power of overall survival (OS) prediction of each measure was determined using Cox regression models. An AI approach was evaluated to predict OS using 5-fold cross-validation of a random survival forest. Model performance was evaluated using the c-index. The top univariate predictors of survival were all heterogeneity features, proportion of lesions increasing (c-index=0.62), number of stable lesions (0.62), number of decreasing lesions (0.60), and number of new lesions (0.59). In an individual scan, the proportion of increasing lesions >29% correlated with poorer progression. The AI model was able to predict responders vs suboptimal responders based on whether they had a treatment intervention or observation alone (35%) (c-index=0.83 in both cases). This study demonstrates that an AI-assisted lesional response analysis can help predict response and prognosis of oligometastatic PC patients. These results support further studies to validate these findings in a prospective cohort.
1758P Body composition meets precision medicine: The prognostic value of sarcopenia in patients (pt) treated with Molecularly Targeted Agents (MTA)
Authors: C. Hierro, L. Notario Rincon, A.M. Esteve Gomez, A. González, A. Llenas, J. Horneros, C. Ibáñez, S. Fontanals, A. Clopes, R. Mesia Nin, L. Arribas
Journal: Annals of Oncology (2023)
1740P Geolocation of respiratory tract cancer and its relationship with chronic exposure to PM2.5 pollutants
Authors: M. González-Escamilla, F. Alcorta-Nuñez, L.E. Reyes-Arreguín, D.C. Pérez-Ibave, C.H. Burciaga Flores, M. Hurtado-Díaz, H. Riojas-Rodríguez, J.L. Texcalac Sangrador, R. Piñeiro-Retif, A. Alcorta-Garza, J.F. Gonzalez, O. Vidal-Gutierrez, M.D.L. Garza Rodriguez
Journal: Annals of Oncology (2023)
1794P Prognostic role of metastatic site in patients with de novo metastatic prostate cancer: A population-based analysis in new hormonal agents era
Authors: E. Yekeduz, M. Eid, E. Saad, R.M. Saliby, K. Semaan, S. Gillessen, T.K. Choueiri, Y. Urun
Journal: Annals of Oncology (2023)
1785P Changes in bone mineral density, trabecular bone score and body composition in metastatic hormone-sensitive prostate cancer (mHSPC) patients randomized to receive androgen deprivation + enzalutamide plus/minus zoledronic acid: The BonEnza study
Authors: A. Dalla Volta, F. Valcamonico, A. Zivi, G. Procopio, P. Sepe, G. Del Conte, N. Di Meo, S. Foti, S. Zamboni, C. Messina, E. Lucchini, A. Rizzi, M. Ravanelli, I. Caramella, M. Zamparini, M. Milella, N. Suardi, R. Maroldi, D. Farina, A. Berruti
Journal: Annals of Oncology (2023)
1754P Towards a next-generation sequencing/comprehensive genomic profiling value framework: Systematic review for identifying new domains and adapting a diagnostic test value framework in Europe
Authors: F. Augustovski, C. Colaci, M. Mills, D. Chavez-Montoya, F. Argento, V. Alfie, A. Pichon Riviere, P. Kanavos, A. Alcaraz
Journal: Annals of Oncology (2023)
1787P Prostate specific membrane antigen positron emission tomography (PSMA PET)-directed clinical outcomes in metastatic hormone-sensitive prostate cancer (mHSPC): Implications for the STAMPEDE2 trial design
Authors: H. Abdel-Aty, N. Hujairi, I. Murray, Y. Yogeswaran, L.R. Murphy, N. van As, L.C. Brown, N.D. James
Journal: Annals of Oncology (2023)
1808P Pain response and health-related quality of life (HRQL) analysis in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel every 2 weeks (16 mg/m2) versus every 3 weeks (25 mg/m2) in the CABASTY phase III trial
Authors: S. Oudard, R. Ratta, E. Voog, P. Barthelemy, A. Thiery-Vuillemin, M. Bennamoun, A. Hasbini, K. Aldabbagh, C. Saldana, G. Von Amsberg, N. Houede, D. Besson, S. Feyerabend, M. Boegemann, A. Falcoz, D. Vernerey, H. Belhouari, S. Kotti, Y. Tran, C. Helissey
Journal: Annals of Oncology (2023)
1805P Efficacy of olaparib (ola) + abiraterone (abi) vs placebo (pbo) + abi in the non-BRCA mutation (non-BRCAm) subgroup of patients (pts) with metastatic castration-resistant prostate cancer (mCPRC) in the PROpel trial
Authors: N. Mehra, N.W. Clarke, A.J. Armstrong, M. Oya, N.D. Shore, G. Procopio, J.D.C. Guedes, C. Arslan, F. Parnis, E. Brown, F. Schlürmann, J.Y. Joung, M. Sugimoto, Y.D. Choi, D. Castellano, Y. Urun, C. Hosius, C. Desai, A. Degboe, F. Saad
Journal: Annals of Oncology (2023)
1767MO External validation of a digital pathology-based multimodal artificial intelligence (MMAI)-derived model in high-risk localized (M0)/metastatic (M1) prostate cancer (PCa) starting androgen deprivation therapy (ADT) in the docetaxel (Doc) or abiraterone (AAP) phase III STAMPEDE trials
Authors: C.T.A. Parker, L. Mendes, E. Grist, V. Liu, D. Van der Wal, J.R. Griffin, E. Chen, P.T. Tran, D. Spratt, L.R. Murphy, A. Sachdeva, S. Lall, M.K. Parmar, M.R. Sydes, L.C. Brown, A. Esteva, F. Feng, N.W. Clarke, N.D. James, G. Attard
Journal: Annals of Oncology (2023)
1793P PPROSTRATEGY: A SOGUG randomized trial of androgen deprivation therapy (ADT) plus docetaxel (dct) +/- nivolumab (nivo) or ipilimumab-nivolumab (ipi-nivo) in high-volume metastatic hormone-sensitive prostate cancer (hvHSPCa) - Safety and toxicity profiles from the pilot phase
Authors: J.A. Arranz Arija, S. Vazquez Estevez, T. Alonso Gordoa, J.M. Sepúlveda Sánchez, B. Perez Valderrama, M.A. Climent Duran, E. Gallardo Diaz, M. Lázaro Quintela, N. Lainez Milagro, M. Domenech Santasusana, M.A. Gonzalez del Alba Baamonde, M.T. Abad Villar, G. Crespo Herrero, C. Alvarez Fernandez, B. Mellado Gonzalez, F.J. Zambrana Tevar, C. Lopez Lopez, S. Perez Ramirez, J.C. Villa Guzmán, J.M. Piulats Rodriguez
Journal: Annals of Oncology (2023)
1734P Early impact of a personalized lung cancer interception program for heavy smokers
Authors: P. Abdayem, L. Veron, G. Garcia, K. Berkane, P. Pradere, T. Pudlarz, K. Ouali, C. Caramella, J. Issard, F. Selhane, T. Ben Ahmed, A. Tardieu, A. Hanna, D. Ammar, H. Caron, B. Ortolan, O. Mercier, D. Planchard, O. Caron, S. Delaloge
Journal: Annals of Oncology (2023)
1764O Timing of radiotherapy (RT) after radical prostatectomy (RP): Final results of RADICALS RT randomised controlled trial
Authors: C. Parker, N. Clarke, A. Cook, H. Kynaston, P. Meidahl Petersen, W. Cross, R. Persad, C. Catton, J. Logue, H.A. Payne, F. Saad, K. Brasso, C. Heath, H. Lindberg, R. Raman, M.A. Røder, A. Zarkar, W.R. Parulekar, M.K. Parmar, M.R. Sydes
Journal: Annals of Oncology (2023)
1783P PROSTRATEGY: A SOGUG randomized trial of androgen deprivation therapy (ADT) plus docetaxel (dct) +/- nivolumab (nivo) or ipilimumab-nivolumab (ipi-nivo) in high-volume metastatic hormone-sensitive prostate cancer (hvHSPCa) - Efficacy results from the pilot phase
Authors: J.A. Arranz Arija, J.M. Piulats Rodriguez, S. Vazquez Estevez, J.M. Sepúlveda Sánchez, T. Alonso Gordoa, B. Perez Valderrama, N. Sala González, M.A. Climent Duran, E. Gallardo Diaz, A. Rodriguez-Vida, C. Caballero Diaz, J. Puente, M.J. Mendez Vidal, E.M.F. Parra, R.C. Martín, J.A. Virizuela Echaburu, M.B.G. Gragera, J. García Sanchez, I. García-Carbonero, J. Carles Galceran
Journal: Annals of Oncology (2023)
1784P Prostate-specific antigen (PSA) outcomes with darolutamide (DARO): Androgen-deprivation therapy (ADT) and docetaxel (DOC) in patients (pts) with high- and low-volume metastatic hormone-sensitive prostate cancer (mHSPC) in ARASENS
Authors: F. Saad, M. Hussain, B. Tombal, K. Fizazi, C.N. Sternberg, E.D. Crawford, M. Boegemann, R. Tutrone, N. Littleton, S. Srinivasan, F. Verholen, I. Kuss, M.R. Smith
Journal: Annals of Oncology (2023)
1789P Low- and high-volume disease in mHSPC: From CHAARTED to PSMA PET
Authors: L.M. Unterrainer, T. Hope, W. Fendler, H. Ndlovu, F. Barbato, M. Sathekge, K. Herrmann, J. Czernin, J. Calais
Journal: Annals of Oncology (2023)
1799P Real-world (RW) treatment (tx) patterns of metastatic prostate cancer (mPCa) with enhanced access to homologous recombination repair (HRR) genomic testing and poly ADP ribose polymerase inhibitor (PARPi)
Authors: S.M. Yip, A.J.W. Gibson, M. Kolinsky, K. Takemura, T. Tucker, M. Freeman, E. Khosh Kish, P. Bose, M. Dean, T.A. Bismar, D.Y.C. Heng, J.D. Ruether, S. North, N. Alimohamed, N.S. Basappa, S. Karim, A. Medina Martin, A. Kinnaird, K.N.N. Chi, S.E. El Hallani
Journal: Annals of Oncology (2023)
1818P Final results from a randomized phase II study of cabazitaxel (CBZ) versus an androgen receptor targeted agent (ARTA) in patients with poor-prognosis castration-resistant prostate cancer (mCRPC)
Authors: K. van der Zande, V. van der Noort, M. Busard, P. Hamberg, S. Ras - van Spijk, J. de Feijter, V. Dezentje, M. Tascilar, D. Houtsma, A. Beeker, P. van den Berg, D. ten Oever, I.M. Oving, W. Zwart, A.M. Bergman
Journal: Annals of Oncology (2023)
1746P Unintended consequences: Working time directives and oncology staff implications
Authors: S. Barry, M.L. O'Connor, C. Moloney, M. Colfer, C. O'Leary, A. Doolan, A. Reilly, G. Lavelle, K. Mckendry, N. Pierce, K. Skehan, C. Kinsella, O.S. Breathnach, W.M. Grogan, B. Hennessy, P.G. Morris, K. Egan, A.G. Murphy, P. Bredin
Journal: Annals of Oncology (2023)
1804P APEX-01: First-in-human phase I/II study of ARX517 an anti- prostate-specific membrane antigen (PSMA) antibody-drug conjugate (ADC) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Authors: J. Shen, R. Pachynski, L.T. Nordquist, N. Adra, M.A. Bilen, R. Aggarwal, Z. Reichert, M. Schweizer, A. Iravani, S. Aung, C. Hessel, S.T. Tagawa
Journal: Annals of Oncology (2023)
1737P Use of the predictive risk model LungFlagTM for lung cancer screening in screening in a Spanish reference center: A cost-effectiveness analysis
Authors: M.E. Olmedo Garcia, L. Gorospe, L.M. Seijo Maceiras, V. Pajares, M. Marzo Castillejo, J.B. Soriano, J.C. Trujillo, N. Arrabal, A. Flores, F. Garcia Verdes-Montenegro, M. Crespo, D. Carcedo, C. Heuser, N. Olghi, E.N. Choman, O. Higuera Gomez
Journal: Annals of Oncology (2023)
1813P Phase I/II trial of oral EPI-7386 in combination with enzalutamide (enz) compared to enz alone in metastatic castration-resistant prostate cancer (mCRPC) subjects: Current phase I (PI) results
Authors: A.L. Laccetti, G. Chatta, C. Kyriakopoulos, N. Iannotti, S.J. Hotte, M.C. Markowski, R. Pili, J. Vuky, J. Zhang, F. Saad, K. Villaluna, B. Younginger, R. Le Moigne, A. Cesano
Journal: Annals of Oncology (2023)
1792P Effects of enzalutamide on overall survival +/- early docetaxel in participants aged less than 70 yrs versus greater than or equal to 70 yrs in ENZAMET (ANZUP 1304)
Authors: L.G. Horvath, I.D. Davis, A. Martin, R. Zielinski, A. Thomson, T.H. Tan, S.K. Sandhu, M.N. Reaume, D. Pook, F. Parnis, S. North, G.M. Marx, J.A. McCaffrey, R.S. McDermott, N. Lawrence, M. Frydenberg, S. Chowdhury, K.N.N. Chi, M.R. Stockler, C. Sweeney
Journal: Annals of Oncology (2023)
1825P Molecular features of circulating tumour cells (CTCs) associate with response to 177Lu-PSMA-617 plus pembrolizumab for metastatic castration resistant prostate cancer (mCRPC)
Authors: D. Goode, S. Keerthikumar, S. Gupta, A.M. Joshua, L. Emmett, M. Crumbaker, T. Singer, E. Lam, L. Fernandez, E. Jimenez, D. Zhang, Y. Lin, R.J. Wenstrup, A. PASAM, R. Hicks, G. Kong, A. Hamid, S.K. Sandhu
Journal: Annals of Oncology (2023)
1768MO Incidence of fracture related hospitalisations in men with de novo high risk localised and metastatic hormone sensitive prostate cancer: Analysis of routinely collected healthcare data from the STAMPEDE docetaxel and zoledronic acid comparisons
Authors: C. Jones, P. Dutey-Magni, L.R. Murphy, M. Murray, J.E. Brown, E. McCloskey, M.K. Parmar, N.D. James, M.R. Sydes, L.C. Brown, N.W. Clarke, A. Sachdeva
Journal: Annals of Oncology (2023)
1773P ICECaP-2: Validation of metastasis-free survival (MFS) as a surrogate for overall survival (OS) in localized prostate cancer (LPC) in a more contemporary era
Authors: W. Xie, P. Ravi, M.E. Buyse, S. Halabi, P.W. Kantoff, O. Sartor, H.R. Soule, N. Clarke, L. Collette, J. Dignam, N.D. James, K. Fizazi, S. Gillessen, N. Mottet, L.R. Murphy, W.R. Parulekar, H. Sandler, B. Tombal, S. Williams, C. Sweeney
Journal: Annals of Oncology (2023)
1810P Association of health-related quality of life with efficacy outcomes in the VISION study of patients with metastatic castration-resistant prostate cancer
Authors: M.J. Morris, A.J. Armstrong, K.N.N. Chi, J.S. de Bono, K. Herrmann, B. Krause, K. Rahbar, O. Sartor, S.T. Tagawa, J. Nagarajah, X.X. Wei, L.T. Nordquist, V.S. Koshkin, F. Saad, A. Vickers, R. Ghouse, J. Wu, O. Mirante, K. Fizazi
Journal: Annals of Oncology (2023)
1822P PSMA-alpha targeted radionuclide therapy (TRT) with or without prior PSMA-beta TRT
Authors: M. Sun, C. Thomas, J. Stangl-Kremser, A. Fajardo, J. Palmer, J. Thomas, S. Huicochea Castellanos, J. Osborne, J. Nauseef, A.M. Molina, C.N. Sternberg, D.M. Nanus, N.H. Bander, S.T. Tagawa
Journal: Annals of Oncology (2023)
1823P The impact of baseline PSMA PET/CT vs. CT on outcomes of Radium-223 therapy in mCRPC patients
Authors: D. Bosch, K. van der Velden, I.M. Oving, D.N.J. Wyndaele, L.E. Weijs, D.W. van Schelven, W.J.G. Oyen, E.T. Te Beek, D.M. Somford, J. Nagarajah, R. Hermsen, N. Mehra, W.R. Gerritsen, M.J. van der Doelen, I.M. van Oort
Journal: Annals of Oncology (2023)
1800P Differential tumor gene-expression profiling of patients (pts) with de-novo metastatic castration-sensitive prostate cancer (dn-mCSPC) versus (vs.) mCSPC relapsing after prior localized therapy (PLT-mCSPC)
Authors: V. Mathew Thomas, B. Chigarira, G. Gebrael, N. Sayegh, N. Tripathi, R. Nussenzveig, G. Galarza Fortuna, K. Sahu, H. Li, A. Srivastava, B. Nordblad, E. Dal, J. Brundage, B.L. Maughan, U. Swami, N. Agarwal
Journal: Annals of Oncology (2023)
1803P Phase I/II study of bavdegalutamide, a PROTAC androgen receptor (AR) degrader in metastatic castration-resistant prostate cancer (mCRPC): Radiographic progression-free survival (rPFS) in patients (pts) with AR ligand-binding domain (LBD) mutations
Authors: D.P. Petrylak, B. Garmezy, J. Shen, A. Rezazadeh Kalebasty, O. Sartor, R. Dreicer, N. Agarwal, M. Hussain, I. Percent, E. Heath, R. Gedrich, T. Yu, D. Healey, J. Parameswaran, C.N. Sternberg, X. Gao
Journal: Annals of Oncology (2023)
1814P First real-life data on [177Lu]Lu-PSMA-617: Descriptive analysis on the largest metastatic castration-resistant prostate cancer (mCRPC) cohort treated in early access in France
Authors: A-L. Giraudet, P. Olivier, V. Massard, A. Flechon, S. Girault, S. Abadie Lacourtoisie, F. Somme, P. Barthelemy, C. Bailly, C. Viala, Y. Godbert, G. Roubaud
Journal: Annals of Oncology (2023)
1806P Efficacy of niraparib and abiraterone acetate plus prednisone (NIRA+AAP) in homologous recombination repair gene-altered (HRR+) metastatic castration-resistant prostate cancer (mCRPC) by tissue and/or plasma assays in the MAGNITUDE trial
Authors: G. Attard, S.K. Sandhu, D. Rathkopf, E. Castro, M. Saad, M.R. Smith, E.J.J. Small, D. Olmos, A.J.P.D.S. Gomes, G. Roubaud, B. Zurawski, E. Efstathiou, D. Wu, B. Diorio, K. Urtishak, U. Singh, Y. Xu, A. Lopez-Gitlitz, A. del Corral, K.N.N. Chi
Journal: Annals of Oncology (2023)
1772MO Pembrolizumab (pembro) plus enzalutamide (enza) and androgen deprivation therapy (ADT) for patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC): Randomized double-blind phase III KEYNOTE-991 study
Authors: C.J. Gratzke, M. Ozguroglu, A. Peer, M.A.N. Sendur, M. Retz, J.C.H. Goh, W.C. Loidl, G. Jayram, S-S. Byun, C. Kwak, M. Kwiatkowski, R. Manneh Kopp, J.C. Vazquez Limon, J.F. Escobar Penagos, U.F.F. De Giorgi, K.M.D. Trindade, C. Niu, Y. Liu, C.H. Poehlein, J.M. Piulats Rodriguez
Journal: Annals of Oncology (2023)
1821P High serum FSH/T ratio as a marker for the development of cardiovascular disease in ADT recipients
Authors: J.H. Pinthus, D. Margel, V. Subramony Gayathri, E. Duceppe, S. Yousef, M. Naeim, M. Khajehei, S. Hopmans, S. Popovic, Y. Ber, D. Heels-Ansdell, P.J. Devereaux, W.C.M. Duivenvoorden
Journal: Annals of Oncology (2023)
1811P Patient-reported outcomes (PROs) in men with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) mutations receiving talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA: Results from a phase III (TALAPRO-2) study
Authors: A.P. Fay, K. Fizazi, N. Matsubara, A.A. Azad, F. Saad, U.F.F. De Giorgi, J.Y. Joung, P.C. Fong, R.J. Jones, S. Zschäbitz, J. Oldenburg, N.D. Shore, C. Dunshee, J. Carles Galceran, P. Cislo, J. Chang, C.G. Healy, A. Niyazov, N. Agarwal
Journal: Annals of Oncology (2023)
1809P Dynamics of plasma tumour DNA and copy number alterations in advanced metastatic castration-resistant prostate cancer (mCRPC) patients treated with cabazitaxel: A prospective biomarker trial
Authors: N. Brighi, D. Wetterskog, G. Gurioli, F. Orlando, V. Conteduca, C. Casadei, C. Lolli, E.F. Giunta, S. Bleve, O. Vainauskas, U. Basso, F. Pierantoni, G. Fornarini, A. Mosca, M. Nicodemo, G.L. Banna, P. Ulivi, F. Demichelis, U.F.F. De Giorgi, G. Attard
Journal: Annals of Oncology (2023)
1786P Effect of rapid ultra-low prostate-specific antigen decline (UL PSA) in TITAN patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) who received apalutamide (APA) plus androgen deprivation therapy (ADT)
Authors: A.S. Merseburger, N. Agarwal, A. Bjartell, H. Uemura, Á. Juárez, A. Bhaumik, J. Boehm, N. Tran, N. Krochmann, M. Nematian, S.D. Mundle, S.D. Brookman-May, S.A. Mccarthy, K.N.N. Chi, S. Chowdhury
Journal: Annals of Oncology (2023)
1801P Impact of intensified androgen deprivation therapy (ADTi) in the metastatic castration-sensitive prostate cancer (mCSPC) setting on metastatic castration-resistant prostate cancer (mCRPC) disease characteristics and survival outcomes
Authors: N. Tripathi, G. Gebrael, N. Sayegh, D. Goel, J. Brundage, B. Nordblad, A. Srivastava, E. Dal, C. Hage Chehade, B. Chigarira, V. Mathew Thomas, K. Sahu, B.L. Maughan, N. Agarwal, U. Swami
Journal: Annals of Oncology (2023)
1791P Molecular profiling and prognostic relevance of low PTEN expression in metastatic hormone-sensitive prostate cancer patients
Authors: M. Garcia De Herreros, N. Jimenez Blasco, O. Reig Torras, V. Ruiz de Porras, J.C. Pardo, A. Font Pous, C. Aversa, L. Ferrer-Mileo, M. Jorda, L. Rodríguez-Carunchio, I. Trias Puigsureda, A. Sánchez-Font, A. Rodriguez-Vida, M. Domenech Santasusana, M. Figols Gorina, M.A. Climent Duran, I. Chirivella Gonzalez, D. Herrero Rivera, E. Gonzalez Billalabeitia, B. Mellado Gonzalez
Journal: Annals of Oncology (2023)
1807P Talazoparib (TALA) plus enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC): Subgroup analyses of the all-comers cohort from TALAPRO-2 by homologous recombination repair (HRR) status
Authors: N. Matsubara, K. Fizazi, A.A. Azad, J. Carles Galceran, A.P. Fay, U.F.F. De Giorgi, J.Y. Joung, P.C. Fong, E. Voog, R.J. Jones, N.D. Shore, C. Dunshee, S. Zschäbitz, L.I. Karsh, P. Barthelemy, X. Lin, C.G. Healy, N. Di Santo, F. Zohren, N. Agarwal
Journal: Annals of Oncology (2023)
1732P War and the fragility of anticancer drug supply networks in Ukraine
Authors: O. Kostenchak-Svystak, D. Kizub, A. Dzhemiliev, I. Huivaniuk, V. Kopetskiy, L. Rieutova, H. Uzlova, I. Matiushenko, M. Kasianchyk, A. Beznosenko, N. Melnitchouk
Journal: Annals of Oncology (2023)
1782P Prostate radiotherapy reduces long-term risk of obstructive uropathy in metastatic hormone sensitive prostate cancer (mHSPC): Results from the STAMPEDE M1|RT comparison
Authors: C. Jones, P. Dutey-Magn, L. Murphy, M. Murray, L. Brown, M. Parmar, N. James, C. Parker, M. Sydes, N. Clarke, A. Sachdeva
Journal: Annals of Oncology (2023)
1721P Self-assessment tool and best-practice sharing to support hospitals in improving the quality of multi-disciplinary teams in lung cancer care
Authors: E. Nadal, M. Gallego Llorente, Y.P. Cui, L. Verbaas, A. Moucquot, H. Moses, T. Finazzi, T.O. Halvorsen, I. Opitz, D. Dellamonica, B. Amesz
Journal: Annals of Oncology (2023)